Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md., June  08, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at 11:30 a.m. EDT, the panel will discuss COVID-19 vaccines. The conversation will consider the complex path from lab to clinical trials, the impact of the evolving science on candidate development and consider how collaboration will bring life-saving vaccines to the world.

Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital

Abbott Labs

Eli Lilly

And they should do so even if their COVID-19 programs aren't as successful as hoped.

$3,000 Invested in These Coronavirus Stocks Could Pay Off Big Time

Pfizer

These companies should benefit from vaccines, tests and beyond.

3 Top Coronavirus Stocks to Buy in  June

Novavax, Inc. (NASDAQ: NVAX) is landing financing deals that could help to successfully develop a vaccine for SARS-CoV, the virus that causes COVID-19.

Novavax Analyst Says DoD Funding Reflects Conviction In Platform, Ability To Deliver On Vaccine

More than $300 million in funding for Novavax’s coronavirus vaccine candidate lifted the shares.

Why Novavax Shares Rose 153.9% in May

Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax Clinches $60M Defense Contract for Coronavirus Vaccine

In return for up to $60 million in funding, the biotech will deliver 10 million doses of NVX-CoV2373 to the military in 2020.

Novavax Wins COVID-19 Vaccine Contract With U.S. Department of Defense

Novavax scores another large grant for its COVID-19 vaccine candidate.

Why Novavax Stock Is Up Big Yet Again Today

Shares of Novavax Inc. NVAX, +0.92% soared 14% in premarket trading Friday, after the biotechnology company said it was awarded a contract by the U.S.

Novavax's stock soars after DoD contract to make its COVID-19 vaccine candidate

GAITHERSBURG, Md., June  04, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

Novavax Awarded Department of Defense Contract for COVID-19 Vaccine

Novavax is well ahead in clinical testing than two of the White House's COVID-19 vaccine finalists.

Why Didn't Novavax Make Trump's Top 5 COVID-19 Vaccine List?

Inovio Pharmaceuticals

Moderna

As companies race to produce a coronavirus vaccine, half of Americans may not be interested, and that haste may be part of the reason.

Could the Rush to a Vaccine Hurt Coronavirus Stocks?

One of the country’s top COVID-19 experts made some discouraging comments regarding a potential vaccine for the coronavirus.

Why Novavax Is Plunging Today

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Dozens of drugmakers are developing COVID-19 vaccines and gearing up to produce billions of doses each year.

Is a COVID-19 Vaccine Supply Glut on the Way?

SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for...

Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine

Investors liked an analyst's higher price target for the biotech stock.

Why Novavax Shares Soared Today

Speculators are buying up shares of Novavax, based on a vast market opportunity for its COVID-19 vaccine. But there's even better news that largely mitigates any downside risk.

Buy Alert: Novavax Stock Is Heading Higher

Arcturus Therapeutics

Dynavax Technologies

iBio

Sorrento Therapeutics Inc

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

7 Red-Hot Biotech Stocks Racing to Develop a Coronavirus Vaccine

After acquiring a Czech company, the clinical-stage biotech will be able to churn out more than 1 billion doses of its SARS-CoV-2 vaccine candidate next year -- if it works.

Novavax Makes a $167 Million Purchase to Boost Its Coronavirus Vaccine Production Capacity

GAITHERSBURG, Md., May  27, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million. The acquisition includes a biologics manufacturing facility and associated assets in Bohumil, Czech Republic. The facility is expected to provide an annual capacity of over 1 billion doses of antigen starting in 2021 for NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

Novavax Expands Large-Scale Global Manufacturing Capacity

Novavax, Inc. (NASDAQ: NVAX), which last month landed CEPI funding for its coronavirus vaccine program, announced Tuesday the  initiation of human studies of its vaccine candidate, NVX-CoV2373.

Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race

"Our target for next year is quite ambitious, but we think doable, which is to produce over a billion doses of vaccine," Novavax CEO Stanley Erck said.

Front-line coronavirus workers could be vaccinated as soon as this year, Novavax CEO says

The biotech hopes to announce results from the phase 1 part of the clinical study in July.

Novavax Begins Early Stage Clinical Study of Its Coronavirus Vaccine Candidate

Gilead Sciences

Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.

Pre-Markets Race Higher on Vaccine Hopes

Novavax (NASDAQ: NVAX) said on Tuesday that it began human trials of its candidate Coronavirus vaccine in Australia. The company said that initial results of the human trial are expected to be released in July 2020.

News for Novavax Stock (NVAX)